See section E4 of the ABR Form.

3 trials

Sponsors

Vertex Pharmaceuticals

Conditions

SFSN small nerve fiber neuropathyfibrocystic disease of the pancreas / monogeic diseasefibrocystic disease of the pancreas / monogenic disease

Phase 2

A Phase 2, Randomized, Double blind, Controlled Study to Evaluate the Safety and Efficacy of VX 440 Combination Therapy in Subjects Aged 12 Years and Older With Cystic Fibrosis

Active, not recruitingNL-OMON45508

Vertex Pharmaceuticalsfibrocystic disease of the pancreas / monogenic disease

Start: 2017-09-25Target: 6Updated: 2024-02-28

A Phase 1/2 Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis

Active, not recruitingNL-OMON47700

Vertex Pharmaceuticalsfibrocystic disease of the pancreas / monogeic disease

Start: 2017-10-11Target: 10Updated: 2024-02-28

VX16-150-102 A Phase 2, Randomized, Double-blind, Placebo-controlled, 6-Week, Parallel-design Study of the Efficacy and Safety of VX-150 in Treating Subjects With Pain Caused by Small Fiber Neuropathy

Active, not recruitingNL-OMON46746

Vertex PharmaceuticalsSFSN small nerve fiber neuropathy

Start: 2018-03-05Target: 4Updated: 2024-02-28